Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Hemophagocytic Lymphohistiocytosis and Gastrointestinal Bleeding: What a Surgeon Should Know

View through CrossRef
This paper presents to the surgical community an unusual and often ignored cause of gastrointestinal bleeding. Hemophagocytic syndrome or hemophagocytic lymphohistiocytosis (HLH) is a rare medical entity characterized by phagocytosis of red blood cells, leucocytes, platelets, and their precursors in the bone marrow by activated macrophages. When intestinal bleeding is present, the management is very challenging with extremely high mortality rates. Early diagnosis and treatment seem to be the most important factors for a successful outcome. We present two cases and review another 18 from the literature.
Title: Hemophagocytic Lymphohistiocytosis and Gastrointestinal Bleeding: What a Surgeon Should Know
Description:
This paper presents to the surgical community an unusual and often ignored cause of gastrointestinal bleeding.
Hemophagocytic syndrome or hemophagocytic lymphohistiocytosis (HLH) is a rare medical entity characterized by phagocytosis of red blood cells, leucocytes, platelets, and their precursors in the bone marrow by activated macrophages.
When intestinal bleeding is present, the management is very challenging with extremely high mortality rates.
Early diagnosis and treatment seem to be the most important factors for a successful outcome.
We present two cases and review another 18 from the literature.

Related Results

GASTROINTESTINAL BLEEDING, DESCRIPTION, ETIOLOGY, EPIDEMIOLOGY, CLASSIFICATION, CLINICAL PRESENTATION, TREATMENT AND PROGNOSIS
GASTROINTESTINAL BLEEDING, DESCRIPTION, ETIOLOGY, EPIDEMIOLOGY, CLASSIFICATION, CLINICAL PRESENTATION, TREATMENT AND PROGNOSIS
Introduction: Gastrointestinal bleeding can be divided into 2 broad categories: upper and lower bleeding. The anatomical landmark that divides upper and lower bleeds is the ligamen...
Bleeding Risk Factors in Thrombocytopenic Patients with Hematologic Malignancies
Bleeding Risk Factors in Thrombocytopenic Patients with Hematologic Malignancies
Introduction Despite prophylactic platelet transfusions, World Health Organization (WHO) grade ≥ 2 bleeding occurs in 50 to 70% of patients with hematologic malignan...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract Introduction Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...
ETIOLOGY OF GASTROINTESTINAL BLEEDING IN CHILDREN
ETIOLOGY OF GASTROINTESTINAL BLEEDING IN CHILDREN
Objectives. Identification of clinical, endoscopic, etiological characteristic of children diagnosed with upper and lower gastrointestinal bleeding. Material and methods. It was co...
Bleeding Disorder Referrals to Hematology Clinic: A Single Institution Experience
Bleeding Disorder Referrals to Hematology Clinic: A Single Institution Experience
BACKGROUND Our tertiary care pediatric hematology/oncology/BMT service receives hundreds of referrals yearly for bleeding disorder evaluation both due to bleeding sy...
Reflections Of Zoltan P. Dienes On Mathematics Education
Reflections Of Zoltan P. Dienes On Mathematics Education
The name of Zoltan P. Dienes (1916- ) stands with those ofJean Piaget, Jerome Bruner, Edward Begle, and Robert Davis as legendary figures whose work left a lasting impression on th...
Analysis of bleeding outcomes in patients with hypoproliferative thrombocytopenia in the A‐TREAT clinical trial
Analysis of bleeding outcomes in patients with hypoproliferative thrombocytopenia in the A‐TREAT clinical trial
AbstractBackgroundDespite prophylactic platelet transfusions, hypoproliferative thrombocytopenia is associated with bleeding; historical risk factors include hematocrit (HCT) 25%, ...
Effects of Tranexamic Acid Prophylaxis on Bleeding Outcomes in Hematologic Malignancy: The a-TREAT Trial
Effects of Tranexamic Acid Prophylaxis on Bleeding Outcomes in Hematologic Malignancy: The a-TREAT Trial
Background: Despite optimal prophylactic platelet (plt) transfusion therapy for severe thrombocytopenia in patients undergoing treatment for hematologic malignancy, WHO Grade 2 or ...

Back to Top